Our objective was to explore the functional interdependence of protein kinase A (PKA) phosphorylation with binding of modulatory FK506 binding proteins (FKBP12/12.6) to the ryanodine receptor (RyR). RyR type 1 or type 2 was prepared from rabbit skeletal muscle or pig cardiac muscle, respectively. In heart failure, RyR2 dysfunction is implicated in fatal arrhythmia and RyR1 dysfunction is associated with muscle fatigue. A controversial underlying mechanism of RyR1/2 dysfunction is proposed to be hyperphosphorylation of RyR1/2 by PKA, causing loss of FKBP12/12.6 binding that is reversible by the experimental inhibitory drug K201 (JTV519). Phosphorylation is also a trigger for fatal arrhythmia in catecholaminergic polymorphic ventricular tachycardia associated with point mutations in RyR2.
Introduction
Skeletal and cardiac muscle ryanodine receptor (RyR) Ca 2þ release channels play a pivotal role in excitation contraction coupling (ECC), physically linking the dyadic space between the sarcolemma and sarcoplasmic reticulum (SR) with the SR Ca 2þ store. 1 ECC is co-ordinately upregulated by adrenergic stimulus via protein kinase A (PKA) phosphorylation of key proteins, as a part of the 'flight or fight' response, which increases Ca 2þ cycling and heart rate. 2 Although RyR1/2 is phosphorylated by PKA, 3 it also responds functionally to the changing Ca 2þ environment within the SR lumen and the dyadic space, invoked by phosphorylation. 4 RyR2 stands centre-stage in ECC-a role highlighted by its implicated dysfunction in heart failure (HF) patients suffering fatal arrhythmia, 5 caused by RyR2 diastolic Ca 2þ leak reversing the Na þ /Ca 2þ exchanger and producing an extra inward Na þ current-a delayed after depolarization (DAD). 6 DADs also underlie fatal arrhythmia in stress-induced catecholaminergic polymorphic ventricular tachycardia (CPVT), in patients carrying a point mutation in the RyR2 gene. 7 These mutational clusters in RyR1 cause malignant hyperthermia (MH) and/or central core disease. 8 The mechanism(s) underlying RyR1/2 dysfunction in HF and CPVT/MH are contentious. Hyperphosphorylation of RyR1 and RyR2 has been proposed to cause the loss of FKBP12/12.6 binding resulting in 'leaky' RyR1/2 channels in both HF 9 and
CPVT. 10 The experimental drugs K201 (JTV519) 11 or S107 are suggested to restore FKBP12/12.6 binding, stabilizing RyR1/2 function in HF, 12 or excessive exercise, 13 although others suggest that K201 acts independently. 14 The evidence for the hyperphosphorylation hypothesis has been challenged, including the increase in phosphorylation in HF, 15, 16 the residues phosphorylated 16, 17 and the loss of FKBP12.6. 18 The discrete domain clusters of RyR1/2 point mutations indicate important interacting conformational domains regulating channel gating. 19 The need to understand dysfunctional mechanisms in the pathological phenotypes of HF and CPVT/MH highlights the paucity of knowledge of the role of phosphorylation and FKBP12/12.6 on normal regulation of RyR1/2 channel gating.
Single-channel studies of PKA phosphorylation have given disparate results-an increase in open probability (P o ), 20 increased Ca 2þ sensitivity and subconductance states attributed to loss of FKBP12.6 9,10 or no effect. 21, 22 PKA phosphorylation overcame the inhibition of RyR channel gating by Mg 2þ and activation by ATP. 21, 23, 24 The binding of FKBP12/12.6 is proposed to stabilize the interaction of the four RyR1/2 subunits decreasing the P o of the channel. 25 -28 In this study, using isolated proteins, we have examined the interaction between RyR1/2 binding to FKBP12/12.6 and the effects of PKA phosphorylation and K201 using Surface Plasmon Resonance (Biacore) to measure equilibrium binding kinetics. 30 Solubilized RyR1/2 was enriched by anion exchange chromatography and elution with a NaCl gradient using FPLC. 29 NaCl was adjusted to 150 mM for the preparation used for Biacore experiments.
Quantity of RyR protein
The RyR1/2 protein was run on a SDS-PAGE (5.5%) with a standard curve of BSA 10 mg to 200 mg/mL (20 mL per lane). 31 The gel was stained with Coomassie (BioRad Biosafe) and the protein content of the RyR band was determined from the BSA standard curve by densitometry, using BioRad Quantity One software. The RyR1 preparations contained 60 mg protein/mL and RyR2 preparations 3 mg/mL. 
Phosphorylation/dephosphorylation of RyR1/2
RyR1 and RyR2 preparations were phosphorylated using the active subunit of PKA. The phosporylation reaction contained 3 mM ATP and 3 mM Mg 2þ , 20 mM PIPES pH 7.1, 0.05% CHAPS, 150 mM NaCl, 5 U of pig PKA active subunit (Sigma), and 60 mg/mL RyR1 protein in a total volume of 200 mL. Specificity for exogenously added PKA activity was tested by the inclusion of the peptide PKI inhibitor 5 -11 (Sigma) at 500 nM and heat-inactivated PKA enzyme (boiled for 20 min) was routinely used as a control for all experiments. Dephosphorylation of RyR2 was also carried out over 1 h using a protein phosphatase 1 (PPI) enzyme kit and buffer by following the manufacturer's protocol (New England Biolabs)-PPI concentration was 1 U in 200 mL of reaction containing 3 mg/mL of RyR2 protein.
The time course of phosphorylation or dephosphorylation was followed by SDS -PAGE and western blotting using an antiphosphoserine Ab (Upstate). The reaction was 'stopped' by the addition of SDS sample buffer. The phosphorylated residues of RyR2 were probed with site-specific anti-phospho-S2030 16 and anti-phosph-S2809. 33 The preparations were used for [ 
Surface plasmon resonance studies
A Biacore 3000 instrument was used. An anti-GST Ab was covalently coupled to the surface of a CM3 chip using a GST coupling kit (Biacore). Recombinant GST-FKBP12/12.6 was bound as the ligand and RyR1/2 used as the analyte. 29 BIA evaluation software calculated the K A , k a , and k d . The binding buffer for all experiments was 150 mM NaCl, 20 mM PIPES, and 0.05% CHAPS, pH 7.1 and either 1 mM EGTA, 1 mM free Ca 2þ (EGTA/Ca 2þ -MaxChelator) or 1 mM Ca 2þ . K201 was included in the binding buffer at the concentrations indicated in the figure legends, also containing RyR1 (60, 30, 15, 7.5, or 3.75 mg/mL), or RyR2 (3, 2, 1, 0.5, and 0.25 mg/mL) for a kinetics experiment. The control for phosphorylated RyR1 experiments was treatment with heat-inactivated PKA and for RyR2 dephosphorylated preparations were compared with those phosphorylated by PKA. Experiments were repeated three or four times using RyR1/2 preparations from different rabbits or pigs.
K201 (JTV519)
K201, 4-[3{1-4-benzyl)piperidinyl}propionyl]-7-methoxy-2,3,4,5-tetrahydra-1,4-benzothiazepine, was a gift from Aetas Pharma, Japan. The stock solution (100 mM) was dissolved in 10% DMSO and for control experiments the equivalent addition of DMSO vehicle was used.
Results

Phosphorylation of RyR1/2
RyR1 phosphorylation by PKA reached its maximum in 1 h, Figure1A and B, and was maintained for 5 h (length of SPR experiments), Figure 1C . The phosphorylation band (Lane 1) was absent using heat inactivated PKA (Lane 2) and in the presence of the specific peptide inhibitor PKI (Lane 3), Figure 1D . RyR2 was endogenously phosphorylated if detected using a generic anti-phospho serine Ab, Figure 1E , Lane 8. Ab specific for phosphorylated S2808 (Lanes 2-4) or S2030 (Lanes 5-7) showed phosphorylation after 1 h of incubation with PKA (Lanes 4 and 7). The controls, dephosphorylated with PP1 for 1 h, showed no phosphorylation with any Ab (Lanes 3, 6, and 9). Figure 2 . Both isoforms showed a biphasic response to free Ca 2þ (pCa). EGTA buffer reduced Ca 2þ to 0.01 mM (pCa8) defining RyR to be in the closed conformation at pCa8 and 70% (RyR1) or 50% (RyR2) closed by pCa3 (1 mM Ca 2þ ). The maximal P oc was achieved between pCa6 and pCa5. There was no significant effect of phosphorylation, Figure 2A (RyR1) and B (RyR2). K201 reduced the P oc at all Ca 2þ concentrations, Figure 2C (RyR1) and D (RyR2). Overall, phosphorylation did not overcome the inhibition by K201, Figure 4E (RyR1) and F (RyR2), although the result was stronger for RyR2.
[
Equilibrium binding kinetics of RyR1/2 to FKBP12/12.6
On the basis of [ First-order reaction kinetics were calculated using the equation in Figure 3A . The equilibrium binding constant, K A , for the RyR1/ FKBP12 interaction, Figure 3B , had the highest affinity when the channel was in the closed conformation and was significantly reduced in the open conformation. The effect of phosphorylation by PKA or the addition of K201 measured at pCa8 was to reduce the affinity for FKBP12/12.6 to the value measured at pCa6. There was no additive effect, when K201 was added to phosphorylated channels. At pCa6, phosphorylation of RyR1 or addition of K201 did not significantly alter the affinity for FKBP12. The dissociation rate constant-k d , Figure 3C , was the parameter which mediated the change in K A and this data was essentially a mirror image of Figure 3B . The association rate constant-k a , Figure 2D , was unchanged in any condition. The data for pCa3 were similar to that for EGTA and [ The equilibrium binding data for RyR2, Figure 4 , gave the same pattern as RyR1. Specificity of binding of RyR2 to GST-FKBP12.6 was shown by FK506 inhibition of ligand binding, Figure 4D . The kinetics was also determined for the binding of RyR2 to FKBP12-shown on the right hand panel of Figure 4A -C. In comparison to that for FKBP12.6, K A was much reduced, the rate of dissociation (k d ) was higher, and the association rate constant (k a ) was slightly reduced. Phosphorylation or K201 addition had no effect. RyR1 in a dose-dependent way to 50% of the control value, Figure 5B , whether the RyR1 preparation was phosphorylated or not. K201 had no additive effect on FKBP12 inhibition. FK506 addition could reverse the effect indicating specificity.
The effect of FKBP12 on the open conformation of RyR1
The potency of K201
A dose response to K201 was determined for [ 3 H]ryanodine binding at pCa5.5, Figure 5B . The maximum inhibition obtained (40%) was the same for both phosphorylated and nonphosphorylated preparations. Equilibrium binding of RyR1 to FKBP 12, using Biacore ( Figure 5C ), showed a maximum inhibition for the closed conformation of 50%. Figure 5 . This inhibition was partially and significantly reversed by phosphorylation and K201, Figure 5D . There was no additive effect when K201 was added to phosphorylated channels. 35 This equivalence does not hold for agents blocking the pore or competing for the ryanodine binding 43 We observed low affinity binding constants for FKBP12, even in the closed conformation, that were unaffected by Ca 2þ concentration, phosphorylation, or K201.
Regulation of RyR1/2 by phosphorylation and FKBP12/12.6
The typical biphasic dose response to Ca 2þ suggested that the removal of FKBP12/12.6 did not adversely effect the Ca 2þ regulation of solubilized RyR1/2 preparations. 44 Adding back FKBP12 to RyR1, Figure 5 , did however reduce P oc by 40-50%, demonstrating a stabilizing function, which was independent of PKA phosphorylation, Figure 4A and B. In most single-channel studies of phosphorylation, the FKBP12/12.6 status is unknown. In one, phosphorylated RyR2 channels opened and closed more rapidly when challenged with rapid pulses of Ca 2þ although overall [ 3 H]ryanodine binding was decreased, 21 supporting the proposal that, to maintain Ca 2þ homeostasis, RyR2 opens and closes more quickly, when components of ECC were phosphorylated, to drive a faster heart rate. 45 Other single-channel bilayer studies of 51 We could not regulate the specific serine residues phosphorylated by PKA. In agreement with others, both S2808 33 and S2030 16 in RyR2 were phosphorylated, detected by specific Abs, Figure 1E . The generic phosphoserine Ab, in addition, detected endogenous phosphorylation of RyR2, requiring dephosphorylation by PP1 as a control.
Mode of action of K201
The action of K201 has been explored extensively in the context of the RyR1/2 hyperphosphorylation hypothesis. Prophylactic administration, in a paced dog model, prevented the haemodynamic symptoms and restored FKBP12.6 binding to levels seen in prepaced hearts. 52 FK506 and PKA phosphorylation could cause domain 'unzipping' and render SR vesicles leaky. 53 In animal and whole cell studies, K201 may not act specifically on RyR2 but through a broad spectrum of pharmacological activity. 54 K201 also enhances renal haemodynamic and excretory properties. 55 It is proposed that the K201 binding domain in RyR2 (2114-2149) can interact with and regulate the central 'zipper' domain. 19 We have shown that K201 can directly inhibit the P oc of RyR1 in FKBP12-stripped preparations-an effect maintained in the presence of PKA phosphorylation (Figure 4) . PKA phosphorylation and K201 could individually reverse the Mg 2þ block of RyR1 P oc , Figure 5D . PKA phosphorylation or K201 acted on the RyR1/2 molecule in the same way by reducing the affinity for FKBP12/12.6 ( Figures 2 and 3 Ryanodine receptor modulation by protein kinase A subunit. 41, 57, 58 Our proposed model would also apply, if FKBP12/ 12.6 bound to different sites on the open and closed conformations but these would have to be masked and unmasked co-ordinately. This model provides a coherent working hypothesis, explaining many of the facets of the relationship between RyR1/2 phosphorylation, FKBP12/12.6, and the action of K201 in HF and CPVT, in the context of normal RyR1/2 function. The evidence points towards the central domain region interaction, as the focus of convergent regulation of RyR1/2, in which FKBP12/12.6, phosphorylation and Mg 2þ exert their counter influences to modulate conformational change. Testing the hypothetical model in Figure 6 (a minimal scheme), may ultimately reconcile modal gating models with conformational rearrangement of the RyR1/2 molecule. 'non-physiological' created by stripping endogenous FKBP12/12.6 during preparation. The grey ovals represent 'domains' of RyR and are illustrative of unknown movements in relation to the pore, which is represented by a space between two vertical rectangles. Association of FKBP12/ 12.6 with RyR1/2 in the presence of Ca 2þ resulted in a decrease in P oc , which was independent of phosphorylation (F -D and G -E). Equilibrium binding kinetics of RyR in the open conformation showed low affinity binding for FKBP12/12.6 (horizontal black oval), D and E, with or without phosphorylation (P). In the closed conformation, B, the affinity for FKBP 12/12.6 was higher (vertical black oval). Phosphorylation reduced the affinity for FKBP12/12.6 (horizontal black oval), while the channel remained closed, B -C, an effect also mediated by K201. This movement may also block Mg 2þ binding sites. We propose that C* represents a transition state from which RyR1/2 can gate more quickly when phosphorylated (dashed arrows). K201, which reduced P oc , was able to stabilize this 'state' (dotted arrows). The D -B transition was mediated by reducing Ca 2þ but FKBP12 and K201 also had an effect. See Discussion section for further explanation.
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